Navigation Links
PARP inhibitor, MK-4827, shows anti-tumor activity in first trial in humans
Date:11/17/2010

d by mutations in the BRCA1/2 genes, such as breast and ovarian cancer, but others had cancers that had arisen sporadically.

The drug was given in pill form once a day, and the researchers found that the maximum tolerated dose was 300 mg a day. Dr Robert Wenham, Clinical Director for Gynecologic Oncology in the Department of Women's Oncology at the Moffitt Cancer Center, who is presenting data on behalf of the participating investigators, said: "MK-4827 is generally well tolerated, with the main dose-limiting toxicity being thrombocytopenia an abnormal decrease in the number of platelets in the circulatory blood. The most common side effects are mild nausea, vomiting, anorexia and fatigue."

The researchers saw anti-tumour responses in both sporadic and BRCA1/2 mutation-associated cancers. Ten patients with breast and ovarian cancers had partial responses, with progression-free survival between 51-445 days, and seven of these patients are still responding to treatment. Four patients (two with ovarian cancer and two with NSCLC) had stable disease for between 130-353 days.

Dr Wenham said: "Most patients in the trial had exhausted standard therapies and those who responded to this drug have benefited. Several patients have been receiving treatment for more than a year. The responses mean that MK-4827 is working as hoped and justify additional studies. Just how well MK-4827 works compared to other treatments is the goal of the next set of studies."

He gave a possible explanation as to why patients with cancers that were not caused by BRCA1/2 mutations also responded to the PARP inhibition. "BRCA is a tumour suppressor gene that assists in repairing double stranded DNA breaks. In BRCA-mutation related cancers, loss of both copies of the gene results in a non-functional protein and thus BRCA deficiency. Because BRCA works with other proteins, BRCA-pathway related deficiency can be seen in the absence of two mutated copies of the BRCA g
'/>"/>

Contact: Emma Mason
wordmason@mac.om
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Wake up, Mom -- study shows gender differences in sleep interruptions
2. Depression linked to HIV risk among South African young people, study shows
3. Gene Therapy Shows Potential Against Heart Failure
4. New treatment for lung cancer shows promise
5. Adding pharmacists to docs offices helps patient outcomes, study shows
6. Hurdles ahead for health care reform primary care model, U-M study shows
7. Pleasurable behaviors reduce stress via brain pathways, research shows
8. New Tool for Rapid Screening of Dementia Shows Promise
9. Louisiana State University Health Sciences Center research shows fish oil component given up to 5 hours after stroke limits brain damage
10. Few eligible young women choose to take HPV vaccine to prevent cervical cancer, study shows
11. Research shows gene-based test can prioritize smokers for lung cancer CT screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... more likely to be diagnosed with more aggressive ... for shorter times than prostate cancer patients who ... , The negative outcomes may be the result ... mentally ill, depression,s impact on biological cancer processes, ... general health and disinterest in receiving more effective ...
(Date:7/10/2014)... Men who experience hot flashes are unlikely to talk ... their silent suffering if they are willing to ... Baylor University case study., After seven weeks of hypnotic ... flashes following prostate cancer surgery showed a drastic decrease ... improvement in sleep quality, according to the study., The ...
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... all types of cancer sends the protein factories in ... tumour,s uncontrolled growth, new research suggests. , Scientists at ... trigger responsible for ratcheting up activity of the endoplasmic ... building blocks cancer cells need to keep growing. , ... controls the flow of messages to the endoplasmic reticulum ...
(Date:7/9/2014)... Cancer Center paint a relatively optimistic picture of women,s ... have spread to the chest wall or skin, but ... skin, regardless of size and whether they have involved ... and called "locally advanced" tumors, suggesting that they are ... survival. Locally advanced breast cancers of this and other ...
Breaking Medicine News(10 mins):Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Urban Aboriginal people face unique health challenges 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3
... CHICAGO, June 24 Bally Total Fitness Holding,Corporation today ... its Chief Executive Officer, effective July 1. Mr. Sheehan ... Directors., Mr. Sheehan, age 46, served as the ... serving as Chief Operating Officer, Mr. Sheehan,served as Executive ...
... control symptoms better, studies show , , TUESDAY, June 24 ... delivery system for an older drug appear to hold ... In the first study, patients taking the drug SLV308 ... tremors and slowness of movement. The results also indicate ...
... announced today Reproductive Health Matters , May 2008 ... Promoting Sexual and Reproductive rights". Under conditions of global ... growing numbers of refugees and internally displaced persons (IDPs) ... right to have rights,. By the end of ...
... Devices known as brain-machine interfaces could someday be ... prosthetic limbs with just their thoughts. Now, University of ... devising a way for computerized devices not only to ... with the brain as it learns. , Instead of ...
... but doing little to ... within the facility, CHICAGO, June 24 The American ... survey asking 1,000 women,their opinions on medical spas. Findings revealed ... customers of these facilities.,Yet half of those women are compromising ...
... The Rehabilitation Institute,of Chicago and MediCom Worldwide, Inc. ... July 18th and 19th. The meeting will be ... University in Chicago., This year, the conference ... scientific agenda will focus on the latest information,issues, ...
Cached Medicine News:Health News:Bally Total Fitness Announces New Chief Executive Officer 2Health News:New Hope for Parkinson's Patients 2Health News:May 2008 issue on conflict and crisis settings: Promoting sexual and reproductive rights 2Health News:Researchers develop neural implant that learns with the brain 2Health News:Researchers develop neural implant that learns with the brain 3Health News:Millennials' Medspa Influence 2Health News:3rd Annual Conference on Pain Jointly Sponsored By Rehabilitation Institute of Chicago and MediCom Worldwide, Inc. 2
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Steroid eluting pacemaker leads...
... Medtronic presents the Streamline family of temporary ... taken the gold standard in temporary pacing ... make them easy to use and less ... 6491 Unipolar Pediatric Temporary Pacing Lead is ...
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Medicine Products: